Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Datasets Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
AAV
MCID: ANC002
MIFTS: 42

Anca-Associated Vasculitis (AAV)

Categories: Bone diseases, Cardiovascular diseases, Rare diseases, Respiratory diseases
Genes Tissues Related diseases Publications Pathways Drugs
Sources

Aliases & Classifications for Anca-Associated Vasculitis

About this section

MalaCards integrated aliases for Anca-Associated Vasculitis:

Name: Anca-Associated Vasculitis 52 58
Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis 52 58 71
Antineutrophil Cytoplasmic Antibody-Associated Vasculitis 52 58
Aav 52 58

Classifications:

MalaCards categories:
Global: Rare diseases
Anatomical: Cardiovascular diseases Respiratory diseases Bone diseases
See all MalaCards categories (disease lists)
Orphanet: 58  
Rare circulatory system diseases
Rare respiratory diseases
Rare systemic and rhumatological diseases


External Ids:

MESH via Orphanet 44 D056648
UMLS via Orphanet 72 C2717865
Orphanet 58 ORPHA156152
UMLS 71 C2717865
Sources

Summaries for Anca-Associated Vasculitis

About this section
NIH Rare Diseases : 52 Antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) is a group of diseases (granulomatosis with polyangiitis , eosinophilic granulomatosis with polyangiitis and microscopic polyangiitis ), characterized by destruction and inflammation of small vessels. The clinical signs vary and affect several organs , such as the kidney, stomach, intestine, and lung. Skin lesions, such as purpura and urticaria , result when blood from small vessels leaks under the skin. AAV occurs when neutrophils attack small and medium vessels of the body. The underlying reason for this remains unclear. Treatment includes cyclophosphamide , glucocorticoids and other autoimmune drugs such as rituximab .

MalaCards based summary : Anca-Associated Vasculitis, also known as anti-neutrophil cytoplasmic antibody-associated vasculitis, is related to microscopic polyangiitis and churg-strauss syndrome. An important gene associated with Anca-Associated Vasculitis is PRTN3 (Proteinase 3), and among its related pathways/superpathways are Innate Immune System and Phagosome. The drugs alemtuzumab and Azathioprine have been mentioned in the context of this disorder. Affiliated tissues include neutrophil, kidney and lung.

Wikipedia : 74 Granulomatosis with polyangiitis (GPA), formerly known as Wegener's granulomatosis (WG), is a long-term... more...

Sources

Related Diseases for Anca-Associated Vasculitis

About this section

Diseases related to Anca-Associated Vasculitis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 633)
# Related Disease Score Top Affiliating Genes
1 microscopic polyangiitis 31.5 MPO HLA-DRB1 CTLA4
2 churg-strauss syndrome 31.5 PRTN3 MPO HMGB1
3 crescentic glomerulonephritis 31.4 PRTN3 MPO
4 glomerulonephritis 31.3 PRTN3 MPO C3
5 vasculitis 31.1 SERPINA1 PRTN3 MPO CTLA4 C3
6 mononeuritis multiplex 31.0 PRTN3 MPO
7 exanthem 30.8 PRTN3 CTLA4
8 multiple cranial nerve palsy 30.7 PRTN3 MPO
9 granulomatosis with polyangiitis 30.7 SERPINA1 PRTN3 MPO HMGB1 CTLA4
10 aortitis 30.7 PRTN3 MPO
11 mastoiditis 30.7 PRTN3 MPO
12 rapidly progressive glomerulonephritis 30.6 PRTN3 MPO C3
13 polyarteritis nodosa 30.6 PRTN3 MPO HLA-DRB1
14 autoimmune vasculitis 30.6 PRTN3 MPO
15 proliferative glomerulonephritis 30.5 MPO C3
16 anti-basement membrane glomerulonephritis 30.4 PRTN3 MPO
17 autoimmune disease 30.4 PRTN3 HLA-DRB1 CTLA4 C3
18 mononeuropathy 30.4 PRTN3 MPO
19 henoch-schoenlein purpura 30.3 PRTN3 MPO
20 pneumonia 30.3 SERPINA1 MPO HMGB1
21 lung disease 30.2 SERPINA1 PRTN3 MPO HMGB1
22 graves' disease 30.2 MPO HLA-DRB1 CTLA4
23 goodpasture syndrome 30.2 PRTN3 MPO HLA-DRB1
24 respiratory failure 30.0 SERPINA1 MPO ANGPT2
25 autoimmune hepatitis 30.0 HMGB1 HLA-DRB1 CTLA4
26 hyperthyroidism 30.0 PRTN3 GHRL CTLA4
27 pulmonary disease, chronic obstructive 30.0 SERPINA1 PRTN3 MPO
28 alpha-1-antitrypsin deficiency 30.0 SERPINA1 PRTN3 MPO
29 anemia, autoimmune hemolytic 29.9 CTLA4 C3
30 hypersensitivity vasculitis 29.8 PRTN3 MPO C3
31 ulcerative colitis 29.8 PRTN3 MPO HLA-DRB1
32 lupus erythematosus 29.7 HMGB1 HLA-DRB1 CTLA4 C3
33 colitis 29.7 MPO HLA-DRB1 CTLA4
34 temporal arteritis 29.7 PRTN3 MPO HLA-DRB1 CTLA4
35 kidney disease 29.7 PRTN3 HMGB1 CTLA4 C3
36 rheumatoid arthritis 29.4 PRTN3 MPO HMGB1 HLA-DRB1 CTLA4
37 thrombotic thrombocytopenic purpura 29.4 HLA-DRB1 C3
38 primary biliary cirrhosis 29.3 PRTN3 HLA-DRB1 CTLA4
39 celiac disease 1 29.2 HLA-DRB1 GHRL CTLA4
40 systemic lupus erythematosus 29.1 PRTN3 MPO HMGB1 HLA-DRB1 CTLA4 C3
41 cholangitis 29.1 PRTN3 MPO HLA-DRB1 CTLA4
42 inflammatory bowel disease 28.4 PRTN3 MPO HMGB1 HLA-DRB1 GHRL CTLA4
43 allergic angiitis 10.8
44 end stage renal failure 10.8
45 hemophilia b 10.6
46 muscular dystrophy 10.5
47 idiopathic interstitial pneumonia 10.5
48 purpura 10.5
49 pulmonary fibrosis 10.5
50 retinal degeneration 10.5

Graphical network of the top 20 diseases related to Anca-Associated Vasculitis:



Diseases related to Anca-Associated Vasculitis
Sources

Symptoms & Phenotypes for Anca-Associated Vasculitis

About this section
Sources

Drugs & Therapeutics for Anca-Associated Vasculitis

About this section

Drugs for Anca-Associated Vasculitis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 67)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
alemtuzumab Approved, Investigational Phase 4 216503-57-0
2
Azathioprine Approved Phase 4 446-86-6 2265
3 Tin Fluorides Phase 4
4 Antiemetics Phase 4
5 Gastrointestinal Agents Phase 4
6 Neuroprotective Agents Phase 4
7 Autonomic Agents Phase 4
8 Protective Agents Phase 4
9
Mycophenolic acid Approved Phase 2, Phase 3 24280-93-1 446541
10
Prednisone Approved, Vet_approved Phase 3 53-03-2 5865
11
Abatacept Approved Phase 3 332348-12-6 10237
12
Methotrexate Approved Phase 3 1959-05-2, 59-05-2 126941
13
leucovorin Approved Phase 3 58-05-9 6006 143
14
Acetaminophen Approved Phase 3 103-90-2 1983
15
Clemastine Approved, Investigational Phase 3 15686-51-8 26987
16
Granisetron Approved, Investigational Phase 3 109889-09-0 3510
17
Ibuprofen Approved Phase 3 15687-27-1 3672
18
rituximab Approved Phase 3 174722-31-7 10201696
19
Methylprednisolone hemisuccinate Approved Phase 3 2921-57-5
20
Methylprednisolone Approved, Vet_approved Phase 3 83-43-2 6741
21
Prednisolone phosphate Approved, Vet_approved Phase 3 302-25-0
22 Prednisolone acetate Approved, Vet_approved Phase 3 52-21-1
23
Prednisolone Approved, Vet_approved Phase 3 50-24-8 5755
24
Folic acid Approved, Nutraceutical, Vet_approved Phase 3 59-30-3 6037
25
Prednisolone hemisuccinate Experimental Phase 3 2920-86-7
26
Dexchlorpheniramine Experimental, Investigational Phase 3 25523-97-1 33036
27 Immunoglobulins Phase 3
28 Antibodies Phase 3
29 Plasma Substitutes Phase 3
30 Immunosuppressive Agents Phase 3
31 Hormone Antagonists Phase 3
32 Anti-Inflammatory Agents Phase 3
33 Antineoplastic Agents, Hormonal Phase 3
34 Hormones Phase 3
35 Complement System Proteins Phase 3
36 Alkylating Agents Phase 3
37 Antimetabolites Phase 3
38 Antitubercular Agents Phase 3
39 Anti-Infective Agents Phase 3
40 Anti-Bacterial Agents Phase 3
41 Antibiotics, Antitubercular Phase 3
42 Folic Acid Antagonists Phase 3
43 Vitamin B Complex Phase 3
44 Vitamin B9 Phase 3
45 Dermatologic Agents Phase 3
46 Folate Phase 3
47 Pharmaceutical Solutions Phase 3
48 Anti-Inflammatory Agents, Non-Steroidal Phase 3
49 Analgesics, Non-Narcotic Phase 3
50 Analgesics Phase 3

Interventional clinical trials:

(show top 50) (show all 64)
# Name Status NCT ID Phase Drugs
1 Alemtuzumab for ANCA Associated Refractory Vasculitis - a Study of Safety and Efficacy Unknown status NCT01405807 Phase 4 Alemtuzumab
2 Short-Course Glucocorticoids and Rituximab in ANCA-Associated Vasculitis Completed NCT02169219 Phase 4 Glucocorticoids;Rituximab
3 Low-dose Glucocorticoids Plus Rituximab Versus High-dose Glucocorticoids Plus Rituximab for Remission Induction in ANCA-associated Vasculitis; a Multicentre, Open Label, Randomised Control Trial Recruiting NCT02198248 Phase 4 Rituximab;Glucocorticoids
4 Maintenance of ANCA Vasculitis Remission by Intermittent Rituximab Dosing Based on B-cell Reconstitution vs a Serologic ANCA Flare Recruiting NCT02749292 Phase 4 Rituximab
5 Prevention of Relapses in PR3-ANCA-associated Vasculitis, a Tailored Approach Terminated NCT00128895 Phase 4 azathioprine
6 Treatment of ANCA-Associated Vasculitides : Corticosteroids and Pulse Cyclophosphamide Followed by Maintenance Therapy With Methotrexate or Azathioprine: a Prospective Multicenter Randomized Trial Unknown status NCT00349674 Phase 3 Azathioprine: 2 mg/kg/day;methotrexate 0.3 mg/kg/week, to a maximum and optimal dose of 25 mg/week
7 Comparative Study of the Efficacy of Induction Therapy With Cyclophosphamide or Mycophenolate Mofetil for Non-Life-Threatening Relapses of PR3- or MPO-ANCA Associated Vasculitis Unknown status NCT00103792 Phase 3 mycophenolate mofetil;cyclophosphamide
8 Efficacy and Tolerance of First-line Treatment With Tocilizumab in Active Takayasu Arteritis French Prospective Multicenter Study Unknown status NCT02101333 Phase 3 Tocilizumab
9 A Randomized, Double-Blind, Active-Controlled, Phase 3 Study to Evaluate the Safety and Efficacy of CCX168 (Avacopan) in Patients With ANCA-Associated Vasculitis Treated Concomitantly With Rituximab or Cyclophosphamide/Azathioprine Completed NCT02994927 Phase 3 CCX168;Prednisone;Cyclophosphamide;Azathioprine
10 MAINtenance of Remission Using RITuximab in Systemic ANCA-associated Vasculitis II Completed NCT01731561 Phase 3 Rituximab (Arm B);Rituximab (Arm A)
11 Randomized Trial of Intravenous Pulse Versus Oral Continuous Cyclophosphamide for Induction of Remission in Systemic ANCA-Associated Vasculitides Completed NCT00430105 Phase 2, Phase 3 cyclophosphamide
12 A Randomised Clinical Trial of Mycophenolate Mofetil Versus Cyclophosphamide for Remission Induction in ANCA Associated Vasculitis. Completed NCT00414128 Phase 2, Phase 3 mycophenolate mofetil;cyclophosphamide
13 MAINtenance of Remission Using RITuximab in Systemic ANCA-associated Vasculitis Completed NCT00748644 Phase 3 Rituximab;Azathioprine
14 Rituximab Therapy for the Induction of Remission and Tolerance in ANCA-Associated Vasculitis (ITN021AI) Completed NCT00104299 Phase 2, Phase 3 Rituximab plus cyclophosphamide placebo (rituximab group);Cyclophosphamide plus rituximab placebo (control group);Azathioprine;Methylprednisolone (or other glucocorticoid);Prednisone
15 Plasma Exchange and Glucocorticoid Dosing in the Treatment of Anti-neutrophil Cytoplasm Antibody Associated Vasculitis: an International Randomized Controlled Trial Completed NCT00987389 Phase 3 Glucocorticoids
16 Maintaining or Stopping Immunosuppressive Therapy in Patients With ANCA Vasculitis and End-stage Renal Disease: a Prospective, Multicenter, Randomized, Open-label, Clinical Trial Recruiting NCT03323476 Phase 3 Maintenance (or initiation) of immunosuppressive treatment: Imurel®, Mabthera®,Cellcept®, Cortancyl®
17 Abatacept (CTLA4-Ig) for the Treatment of Relapsing, Non-Severe, Granulomatosis With Polyangiitis (Wegener's) (ABROGATE) Recruiting NCT02108860 Phase 3 Abatacept;placebo
18 Evaluating Favorable, Immunological Effects of Rituximab With Cyclophosphamide Compared to Rituximab Alone in AAV Patients Recruiting NCT03942887 Phase 3 Rituximab;endoxan;Methylprednisolone;Prednisolone
19 The Assessment of Prednisone In Remission Trial (TAPIR) - Patient Centric Approach Recruiting NCT01933724 Phase 3 5 mg prednisone;0 mg prednisone
20 The Assessment of Prednisone In Remission Trial (TAPIR) - Centers of Excellence Approach Recruiting NCT01940094 Phase 3 5 mg Prednisone;0 mg Prednisone
21 The Effect of Some Drugs Used in Treatment of Vasculitis on the Complement System in Children Attending Assiut University Hospital. Recruiting NCT03692416 Phase 3 Ibuprofen;Prednisone;Methotrexate
22 Extended Follow Up of the Mainritsan 2 Study. Comparison Between a Long Term and a Conventional Maintenance Treatment With Rituximab: a Placebo- Controlled Randomized Trial Active, not recruiting NCT02433522 Phase 3 rituximab;Placebo
23 An International, Open Label, Randomised Controlled Trial Comparing Rituximab With Azathioprine as Maintenance Therapy in Relapsing ANCA-associated Vasculitis Active, not recruiting NCT01697267 Phase 3 Azathioprine
24 Efficacy and Safety of Rituximab in the Treatment of Good Prognosis Microscopic Polyangiitis Not yet recruiting NCT03920722 Phase 3 Rituximab;placebo
25 Does CMV Reactivation Cause Functional Impairment of CMV Specific CD4+ T-cells? The Potential for Valaciclovir to Prevent CMV-mediated Adverse Modulation of the Immune System in Patients With ANCA-associated Vasculitis Unknown status NCT01633476 Phase 2 Valaciclovir
26 A Randomized, Double-Blind, Placebo-Controlled, Dose Assessment Phase 2 Study to Evaluate the Safety and Efficacy of CCX168 in Subjects With Anti-Neutrophil Cytoplasmic Antibody (ANCA)-Associated Vasculitis Completed NCT02222155 Phase 2 CCX168 low dose plus standard of care;CCX168 high dose plus standard of care
27 Pilot Study of Rituximab Therapy for Systemic Lupus Erythematosus (SLE) and Vasculitis Resistant to Conventional Therapy Completed NCT00293072 Phase 2 Rituximab
28 Phase II Pilot Cohort Study to Investigate the Safety and Efficacy of Infliximab as Additional Therapy in the Treatment if Anti-Neutrophil Cytoplasm Antibody Associated Vasculitis Completed NCT00753103 Phase 2 Cyclophosphamide;Prednisolone;Azathioprine;Mycophenolate mofetil;Methylprednisolone
29 A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study to Evaluate the Safety and Efficacy of CCX168 in Subjects With Anti-Neutrophil Cytoplasmic Antibody (ANCA)-Associated Vasculitis on Background of Cyclophosphamide or Rituximab Treatment Completed NCT01363388 Phase 2 Placebo;CCX168
30 A Randomised, Double Blind, Controlled Mechanistic Study of Rituximab and Belimumab Combination Therapy in PR3 ANCA-associated Vasculitis Recruiting NCT03967925 Phase 2 Belimumab
31 Multicenter Randomized Controlled Trial Comparing Immunogenicity and Safety of Two Innovative Anti-pneumococcal Vaccine Strategies to Standard Vaccination Regimen in Patients With ANCA-associated Vasculitis Receiving Rituximab Therapy Recruiting NCT03069703 Phase 2 Rituximab
32 A Pilot Study to Evaluate the Efficacy and Safety of Pirfenidone in Patients With Pulmonary Fibrosis With Anti-myeloperoxydase (MPO) Antibodies or With Anti-MPO Associated Vasculitis." Recruiting NCT03385668 Phase 2 Pirfenidone
33 Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Phase II Efficacy and Safety Study of IFX-1 in Add-On to Standard of Care in Granulomatosis With Polyangiitis (GPA) and Microscopic Polyangiitis (MPA) Recruiting NCT03712345 Phase 2 IFX-1;IFX-1;Placebo
34 Acquired Immunodeficiency in ANCA (Antineutrophil Cytoplasmic Antibody) Associated Vasculitis Not yet recruiting NCT03514979 Phase 2
35 A Pilot Study Examining the Effect of Abatacept in ANCA Associated Vasculitis Terminated NCT00482066 Phase 2 Abatacept (Orencia)
36 A Pilot Study on the Use of Rituximab in the Treatment of Churg- Strauss Syndrome With Renal Involvement Terminated NCT00424749 Phase 2 Rituximab;Prednisone
37 Retinoids in ANCA Small Vessel Vasculitis: Silencing Autoantigens Withdrawn NCT01275274 Phase 2 Retinoic acid;Standard of care
38 Targeting Complement Activation in Antineutrophil Cytoplasmic Autoantibodies (ANCA)-Vasculitis Withdrawn NCT01275287 Phase 2 Standard of care treatment;eculizumab
39 A Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy, Safety, and Tolerability of Blisibimod in Addition to Methotrexate During Induction of Remission in Subjects With ANCA-Associated Small Vessel Vasculitis Withdrawn NCT01598857 Phase 2 Blisibimod;Placebo
40 A Pilot Study of Mycophenolate Mofetil (MMF) in Patients With p-ANCA Microscopic Polyangiitis and Mild to Moderate Renal Dysfunction. Completed NCT00405860 Phase 1 CellCept (mycophenolate mofetil)
41 Immunogenicity of a Combined Anti-pneumococcal Vaccine Schedule in Patients With ANCA-associated Vasculitis: a Pilot Study Following New Vaccine Recommendations. PneumoVas Pilot 2 Unknown status NCT02463578
42 Cohort Study of Chinese Patients With Pulmonary Vasculitis Unknown status NCT02126098
43 Differing Levels of Positive Anti-Neutrophil Cytoplasm Antibody (ANCA) Test and Their Correlation With Vasculitis or Malignancy or Chronic Inflammation Unknown status NCT02180126
44 A Qualitative Study Using Interviews With Patients Who Have Anti-neutrophil Cytoplasm Antibody (ANCA) Associated Vasculitis, to Develop a Patient Reported Outcome (PRO) Measure Unknown status NCT01729624
45 Neutrophils Function and Identification of Prognostic Factors in Granulomatosis With Polyangiitis (Formerly Named Wegener's Granulomatosis). Unknown status NCT01862068
46 Eosinophilic Granulomatosis With Polyangiitis Cohort Unknown status NCT03036670
47 Residual Anti-pneumococcal Immunity After Pneumococcal Immunization in ANCA-associated Vasculitis. PneumoVas Pilot 1 Completed NCT02463539
48 Mycophenolate Mofetil Versus Cyclophosphamide in the Induction Treatment of ANCA Associated Vasculitis Completed NCT00301652 mycophenolate mofetil
49 The ANCA Vasculitis Questionnaire (AAV-PRO©) Completed NCT02507024
50 A Prospective Cohort Study in 6 Swiss Rheumatology Centres and 4 Travel Clinics on the Immunogenicity and Safety of Tetanus and Hepatitis A Vaccine in Patients With Rheumatoid Arthritis, Axial Spondyloarthritis and Vasculitis and Healthy Controls Completed NCT01947465

Search NIH Clinical Center for Anca-Associated Vasculitis

Sources

Genetic Tests for Anca-Associated Vasculitis

About this section
Sources

Anatomical Context for Anca-Associated Vasculitis

About this section

MalaCards organs/tissues related to Anca-Associated Vasculitis:

40
Neutrophil, Kidney, Lung, B Cells, Heart, T Cells, Bone
Sources

Publications for Anca-Associated Vasculitis

About this section

Articles related to Anca-Associated Vasculitis:

(show top 50) (show all 2036)
# Title Authors PMID Year
1
Urinary mitochondrial DNA is a useful biomarker for assessing kidney injury of antineutrophil cytoplasmic antibody -associated vasculitis. 61
31758933 2020
2
Relationship between autoantibodies to erythropoietin receptor and renal outcome in patients with anti-neutrophil cytoplasmic antibody-associated vasculitis. 61
32024392 2020
3
Error in the dosage of Methotrexate in the EULAR/ERA-EDTA recommendations for the management of ANCA-associated vasculitis. 61
32024649 2020
4
Reduced activated regulatory T cells and imbalance of Th17/activated Treg cells marks renal involvement in ANCA-associated vasculitis. 61
31837507 2020
5
Long-term follow-up characteristics of patients with anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) receiving chronic hemodialysis at a single center. 61
31641958 2020
6
Urinary soluble CD163 and monocyte chemoattractant protein-1 in the identification of subtle renal flare in anti-neutrophil cytoplasmic antibody-associated vasculitis. 61
30380100 2020
7
The complexity of classifying ANCA-associated small-vessel vasculitis in actual clinical practice: data from a multicenter retrospective survey. 61
31385079 2020
8
Infectious profile in inpatients with ANCA-associated vasculitis: a single-center retrospective study from Southern China. 61
31576488 2020
9
Effect of high mobility group box 1 on Toll-like receptor 9 in B cells in myeloperoxidase-ANCA-associated vasculitis. 61
31790283 2020
10
Therapeutic Myeloperoxidase Inhibition Attenuates Neutrophil Activation, ANCA-Mediated Endothelial Damage, and Crescentic GN. 61
31879336 2020
11
Coxiella burnetii endocarditis as a possible cause of ANCA-associated vasculitis. 61
32025729 2020
12
Pathological and Radiological Correlation in Prolonged Myeloperoxidase Anti-neutrophil Cytoplasmic Antibody-related Diffuse Alveolar Hemosiderosis. 61
31588078 2020
13
A case of anti-neutrophil cytoplasmic antibody-associated vasculitis with anti-glomerular basement membrane antibodies that was successfully treated with mizoribine as a safe and effective remission maintenance therapy with prednisolone and plasma exchange. 61
31612361 2020
14
Validation of a renal risk score in a cohort of ANCA-associated vasculitis patients with severe kidney damage. 61
31970548 2020
15
ANCA associated vasculitis. 61
32005600 2020
16
Complications of therapy for ANCA-associated vasculitis. 61
31967652 2020
17
Relapse in Anti-Neutrophil Cytoplasm Antibody (ANCA)-Associated Vasculitis. 61
31922056 2020
18
[ANCA and anti-MBG double-positive vasculitis: An update on the clinical and therapeutic specificities and comparison with the two eponymous vasculitis]. 61
31839271 2020
19
Long-term outcome of renal transplantation in childhood-onset anti-neutrophil cytoplasmic antibody-associated vasculitis. 61
31944501 2020
20
Serum IgG4 level and IgG4 subclass of ANCA as disease biomarker for ANCA-associated vasculitis. 61
31811700 2020
21
Severe proximal muscle weakness with normal CK as a presenting feature of ANCA-associated vasculitis. 61
31969410 2020
22
Multivariable index for assessing the activity and predicting all-cause mortality in antineutrophil cytoplasmic antibody-associated vasculitis. 61
31441120 2020
23
Complement alternative pathway in ANCA-associated vasculitis: Two decades from bench to bedside. 61
31734405 2020
24
Alveolar haemorrhage in ANCA-associated vasculitis: Long-term outcome and mortality predictors. 61
31926833 2020
25
Concurrent anti-neutrophil cytoplasmic antibody-associated glomerulonephritis and IgG4-associated tubulointerstitial nephritis with C3 glomerulonephritis: A case report. 61
32000387 2020
26
Propylthiouracil-induced antineutrophil cytoplasmic antibody-associated vasculitis and agranulocytosis in a patient with Graves' disease. 61
31917676 2020
27
No evident association of nasal carriage of Staphylococcus aureus or its small-colony variants with cotrimoxazole use or ANCA-associated vasculitis relapses. 61
31834404 2020
28
Relapses in patients with anti-neutrophil cytoplasmic antibody-associated vasculitis: a retrospective study. 61
31907693 2020
29
Bilateral Vision Loss with p-ANCA Associated Lymphocytic Vasculitis. 61
30427747 2020
30
Elevated levels of d-dimer are associated with inflammation and disease activity rather than risk of venous thromboembolism in patients with granulomatosis with polyangiitis in long term observation. 61
31923773 2020
31
Predictors of fatal and non-fatal cardiovascular events in ANCA-associated vasculitis: data from the Toronto CanVasc cohort. 61
31958575 2020
32
ANCA-Associated Vasculitis: Core Curriculum 2020. 61
31358311 2020
33
Clinical implication of chronic paranasal sinusitis for the classification of microscopic polyangiitis. 61
31573728 2020
34
Asthma control in eosinophilic granulomatosis with polyangiitis treated with rituximab. 61
31897956 2020
35
Propionibacterium acnes-associated chronic hypertrophic pachymeningitis followed by refractory otitis media: a case report. 61
31918670 2020
36
Usual interstitial pneumonia in ANCA-associated vasculitis: A poor prognostic factor. 61
31570253 2020
37
A novel 4-dimensional live-cell imaging system to study leukocyte-endothelial dynamics in ANCA-associated vasculitis. 61
31865776 2019
38
Anti-neutrophil Cytoplasmic Antibodies (ANCA) as Disease Activity Biomarkers in a "Personalized Medicine Approach" in ANCA-Associated Vasculitis. 61
31879818 2019
39
Prevalence and management of cardiovascular risk factors in ANCA-associated vasculitis. 61
31243446 2019
40
Glucocorticoid-free induction regimen in severe ANCA-associated vasculitis using a combination of rituximab and eculizumab. 61
31102526 2019
41
All-cause and cause-specific mortality in ANCA-associated vasculitis: overall and according to ANCA type. 61
31846030 2019
42
Update on ANCA-associated vasculitis: from biomarkers to therapy. 61
31301058 2019
43
Drug-induced anti-neutrophil cytoplasmic antibody-associated vasculitis. 61
31856057 2019
44
Kidney transplantation in ANCA-associated vasculitis. 61
31471816 2019
45
Controlling Nutritional Status Score is Associated with All-Cause Mortality in Patients with Antineutrophil Cytoplasmic Antibody-Associated Vasculitis. 61
31769247 2019
46
Double positivity for antineutrophil cytoplasmic antibody (ANCA) and anti-glomerular basement membrane antibody could predict end-stage renal disease in ANCA-associated vasculitis: a monocentric pilot study. 61
31802348 2019
47
Predictor of depressive disorders in patients with antineutrophil cytoplasmic antibody-associated vasculitis. 61
31312987 2019
48
Subcutaneous Immunoglobulin for Antibody Deficiency in Antineutrophil Cytoplasmic Antibody (ANCA)-associated Vasculitis. 61
31938649 2019
49
Autologous haematopoietic stem cell transplantation (HSCT) for anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis: a retrospective survey of patients reported to European Society for Blood and Marrow Transplantation (EBMT) registry. 61
31848450 2019
50
Antineutrophil Cytoplasmic Antibodies Testing and Interpretation. 61
31668268 2019
Sources

Variations for Anca-Associated Vasculitis

About this section
Sources

Expression for Anca-Associated Vasculitis

About this section
Search GEO for disease gene expression data for Anca-Associated Vasculitis.
Sources

Pathways for Anca-Associated Vasculitis

About this section

Pathways related to Anca-Associated Vasculitis according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Innate Immune System 65
Show member pathways
 13.29 SERPINA1 PRTN3 MPO HMGB1 HLA-DRB1 CTLA4
2
Phagosome 36
10.98 MPO HLA-DRB1 C3
3
amb2 Integrin signaling 1
10.94 MPO HMGB1
4
Platinum Pathway, Pharmacokinetics/Pharmacodynamics 60
10.42 MPO HMGB1
Sources

GO Terms for Anca-Associated Vasculitis

About this section

Cellular components related to Anca-Associated Vasculitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 endoplasmic reticulum lumen GO:0005788 9.5 SERPINA1 GHRL C3
2 extracellular region GO:0005576 9.5 SERPINA1 PRTN3 MPO HMGB1 GHRL C3
3 secretory granule lumen GO:0034774 9.43 HMGB1 GHRL C3
4 azurophil granule lumen GO:0035578 9.33 PRTN3 MPO C3
5 extracellular space GO:0005615 9.17 SERPINA1 PRTN3 MPO HMGB1 GHRL C3

Biological processes related to Anca-Associated Vasculitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 immune system process GO:0002376 9.56 HMGB1 HLA-DRB1 CTLA4 C3
2 negative regulation of T cell proliferation GO:0042130 9.43 HLA-DRB1 CTLA4
3 negative regulation of blood vessel endothelial cell migration GO:0043537 9.4 HMGB1 ANGPT2
4 positive regulation of insulin secretion involved in cellular response to glucose stimulus GO:0035774 9.37 HLA-DRB1 GHRL
5 negative regulation of interferon-gamma production GO:0032689 9.32 HMGB1 HLA-DRB1
6 positive regulation of vascular endothelial cell proliferation GO:1905564 9.16 HMGB1 GHRL
7 neutrophil degranulation GO:0043312 9.02 SERPINA1 PRTN3 MPO HMGB1 C3
8 inflammatory response to antigenic stimulus GO:0002437 8.96 HMGB1 HLA-DRB1
Sources

Sources for Anca-Associated Vasculitis

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....